How do generic bosulif versions compare in price?

How much cheaper are generic bosulif versions?

Generic versions of bosulif typically sell for 50 to 80 percent less than the brand-name price. The drop happens once multiple manufacturers gain FDA approval and start competing on price.

What drives the price difference between brand and generic bosulif?

Bosulif is the brand-name version of bosutinib, a tyrosine kinase inhibitor approved for chronic myeloid leukemia. The company that holds the original patents charges a high initial price to recover research costs. Once patents expire or are successfully challenged, generic manufacturers can produce the same active ingredient without bearing those costs. The resulting competition pulls prices down.

When can generics enter the market?

Generic bosutinib entered the U.S. market after Pfizer lost some patent protection on the compound itself. First-to-file applicants received 180-day exclusivity, limiting price drops at start. Later entrants further lowered prices through ordinary market competition.

Are there still patent disputes affecting price?

Yes. Ongoing litigation between Pfizer and generic manufacturers continues to influence launch timing and pricing. Companies challenge remaining method-of-use or formulation patents in court or through inter partes review. Successful challenges accelerate generic availability.

What role does DrugPatentWatch.com play in tracking these changes?

DrugPatentWatch.com lists every submitted and granted patent covering bosutinib, plus litigation status and estimated launch dates. Users track remaining exclusivity periods and anticipate price reductions when additional generics launch.